Home » Newsletters » BioWorld Science

BioWorld Science

May 17, 2012

View Archived Issues

Novartis identifies new class of compounds for treating cystic fibrosis

Daiichi Sankyo profiles highlights of fiscal 2011

Roche reports novel agents for raising HDL cholesterol

First results for phase II COMPLETE study of eculizumab presented

Genetic basis of TAR syndrome uncovered

Dainippon Sumitomo Pharma updates activities of fiscal 2011

Spanish researchers patent new agents for Gaucher's disease

Novel monoglyceride lipase inhibitors presented by Janssen Pharmaceutica

Elevation Pharmaceuticals reports phase IIb results for EP-101 in COPD

InterMune patents new agents for hepatitis and liver disorders

Cytomedix expands phase II RECOVER-Stroke study

Astellas Pharma and CoMentis present novel compounds for Alzheimer's disease

Biosceptre collaborates with Australian facilities on cancer antibody research

Achaogen provides update on plazomicin and ACHN-975 programs

New inhibitors of serotonin receptor binding synthesized at Epiomed Therapeutics

Abbott presents clinical results for their antiviral candidate ABT-072

Major Alzheimer's disease prevention study commences

Fibrocell Science enters two new agreements

Pfizer reports topline results from phase III Torisel study

Antibodies targeting misfolded Fas receptor protein disclosed

BG Medicine obtains expanded indication for Galectin-3 test in E.U., files for clearance in U.S.

Repros submits documents to FDA for Androxal SPA

Amgen provides updated blinatumomab results

Neuren Pharmaceuticals and FDA hold pre-IND meeting for NNZ-2566

Ark Therapeutics gives update on VEGF-D adenoviral vector treatment study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...